Enliven Therapeutics Inc

ELVNNASDAQ · US

Holders

REDUCEDT+7
Hohl Benjamin
Enliven Therapeutics Inc · NASDAQ
−4,630 sh · $270.2K
Filed 19 Aug 2026SEC Form 4view source
REDUCEDT+7
Collins Helen Louise
Enliven Therapeutics Inc · NASDAQ
−1,100 sh · $65.3K
Filed 19 Aug 2026SEC Form 4view source
REDUCEDT+7
Collins Helen Louise
Enliven Therapeutics Inc · NASDAQ
−3,900 sh · $227.6K
Filed 19 Aug 2026SEC Form 4view source
ACQUIREDT+7
Collins Helen Louise
Enliven Therapeutics Inc · NASDAQ
+5,000 sh · $12.4K
Filed 19 Aug 2026SEC Form 4view source
REDUCEDT+7
Hohl Benjamin
Enliven Therapeutics Inc · NASDAQ
−1,388 sh · $82.4K
Filed 19 Aug 2026SEC Form 4view source
DISCLOSEDStale
Duquesne Family Office
Enliven Therapeutics Inc · NASDAQ
947,405 sh · $19.4M
Filed 30 Sept 2025SEC 13Fview source
DISCLOSEDStale
Duquesne Family Office
Enliven Therapeutics Inc · NASDAQ
463,000 sh · $9.3M
Filed 30 Jun 2025SEC 13Fview source
DISCLOSEDStale
BlackRock
Enliven Therapeutics Inc · NASDAQ
2,730,773 sh · $63.8M
Filed 30 Jun 2024SEC 13Fview source